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The role that amniotic fluid (AF) may play in HIV vertical infection is
unresolved. We used the FIV-infected cat model to study this question. We
hypothesized that AF may be a source of fetal infection if the virus is present in
the fluids. However, virus neutralizing (VN) antibodies in AF may limit vertical
transfer. Fetuses were delivered from FIV-infected queens by cesarean section
at early and late gestation. AFs were aspirated from intact fetal membranes and
tested for viral antigen and RNA and for FIV-specific antibody. Randomlyselected samples were tested for VN activity using a syncytium reduction assay.
Neither FIV antigen nor RNA was detected in any AFs. AFs and parallel serum
samples from early and late pregnancy were positive for FIV-specific antibody.
VN activity was detected in three early-term AFs and a parallel serum, but not
late-term AFs. AF appears to play no appreciable role in FIV vertical
transmission.

DEDICATION

I would like to dedicate this work to one of my best friends, Demarcus
Antonio Travis. I hope that my hard work, determination, and sacrifice during my
years as a mastered student will inspire him to follow his dreams and pursue all
opportunities in spite of any hardships.

ii

ACKNOWLEDGEMENTS

Many people have contributed to my completion of this degree through
guidance, support, friendship, and love. First and foremost, I want to thank God
for blessing me and giving me strength for the past 25 years and for many more.
I would like to thank my family, especially my mother, for the financial and moral
support. Secondly, I want to thank my close friends who dried my tears during
the hard times and offered me their loyal friendship. I could not have completely
this degree without my family and close friends. I am eternally grateful to Dr.
Pharr and Dr. Wise for serving as my committee members. Your efforts in my
education have benefited me tremendously. I would like to thank my laboratory
colleagues, Crystal Boudreaux, Nikki Lockett, and Veronica Scott, for always
lending a helping hand whenever I needed it. To my sorors of Delta Sigma
Theta, thank you for the laughter, memorable times, and encouraging words.
Lastly, I want to express never-ending gratitude to Dr. Karen Coats for educating
and guiding me through my master’s work. I could not have asked for a better
major professor. Your generosity, advice, expertise, and understanding are
greatly appreciated and I cannot thank you enough for all that you have done for
me. Thank you all!!

iii

TABLE OF CONTENTS

DEDICATION ........................................................................................................ ii
ACKNOWLEDGEMENTS ..................................................................................... iii
LIST OF TABLES ................................................................................................. vi
LIST OF FIGURES .............................................................................................. vii
CHAPTER
I. REVIEW OF PERTINENT LITERATURE .................................................. 1
FIV: A Model for HIV ................................................................................. 2
Mother to Child Transmission (MTCT) and Pregnancy Outcome ............. 3
Viral Contamination of Amniotic Fluid ....................................................... 5
Immunological and Neutralizing Responses ............................................. 6
Significance and Purpose of Study ........................................................... 8
References ............................................................................................... 9
II. ANALYSIS OF AMNIOTIC FLUID AND MATERNAL SERA FROM
FELINE IMMUNODEFICIENCY VIRUS (FIV)- INFECTED CATS FOR
VIRUS-SPECIFIC ANTIBODY AND VIREMIA ......................................... 13
Abstract ................................................................................................... 13
Introduction ............................................................................................. 14
Materials and Methods ............................................................................ 17
Animals and Virus .............................................................................. 17
Collection of Amniotic Fluid and Serum ............................................. 17
FIV Antibody Detection using SNAP FIV/FeLV ELISA Kits ............... 18
FIV Antibody Detection using the Petchek FIV Antibody Test Kit ...... 18
Whole Virus Purification .................................................................... 19
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS-PAGE) ................................................................................. 19
Western Blot Procedure .................................................................... 20
CrFK Cell Culture and Infection ......................................................... 20
Virus Neutralization Assay (Syncytium Reduction Assay) ................. 21
iv

Quantification of FIV Antigen in Amniotic Fluid .................................. 23
RNA Extraction .................................................................................. 23
Quantification of FIV RNA using Real-Time Reverse
Transcriptase (RT) PCR ............................................................... 23
Statistical Analysis ............................................................................. 26
Results .................................................................................................... 26
I. Viral Load and FIV-specific Antibody in Amniotic Fluids (AF) ......... 26
Viral Load and FIV-specific Antibody Detection in Early-term
AF Samples ............................................................................ 26
Viral Load and FIV-specific Antibody Detection in Late-term
AF Samples ............................................................................ 26
II. Relative Level of FIV-specific Antibody in AF ................................ 31
Relative FIV-specific Antibody Levels for Early-term AF .............. 31
Relative FIV-specific Antibody Levels for Late-term AF ............... 33
Comparisons of FIV Seroreactivity in Serum from Early
Infection vs. Termination .......................................................... 35
III. Syncytium Reduction with AF and Terminal Serum Samples ....... 38
Early Pregnancies ........................................................................ 38
Late Pregnancies ......................................................................... 45
Discussion .............................................................................................. 51
Acknowledgements ................................................................................. 57
References ............................................................................................. 58
III. SUMMARY .............................................................................................. 62
References ............................................................................................. 65

v

LIST OF TABLES

2.1.

Oligonucleotides used for real-time RT-PCR gene expression
analysis ................................................................................... 25

3.1.

Viral Load and IgG Detection of the Early Term Amniotic Fluid
Samples ................................................................................... 28

3.2.

Viral Load and IgG Detection of the Late Term AF Samples ............. 29

vi

LIST OF FIGURES

2.1.

Virus Neutralization Assay Design...................................................... 22

3.1.

SNAP ELISAs for Early and Late Term AF Sample .......................... 30

3.2.

Relative Levels of FIV-specific Antibody in Early-term AF
Samples. OD of 650 nm were determined for each sample
and controls (included in kit), and sample to positive (S/P)
ratios were calculated. The 0.5 S/P indicates the
positive/negative threshold for antibody detection. All S/P
ratios above 0.5 were considered positive. ................................... 32

3.3.

Relative Levels of FIV-specific Antibody in Late –term AF
Samples. OD 650 nm were determined for each sample and
controls (included in kit), and sample to positive (S/P) ratios
were calculated. The 0.5 S/P indicates the positive/negative
threshold for antibody detection. All S/P ratios above 0.5
were considered positive. .............................................................. 34

3.4.

Relative Levels of FIV-specific Antibody in Serum Samples.
OD 650 nm were determined for each sample and controls
(included in kit), and sample to positive (S/P) ratios were
calculated. The 0.5 S/P indicates the positive/negative
threshold for antibody detection. All S/P ratios above 0.5
were considered positive. ............................................................. 36

3.5.

Western blot analysis of longitudinal serum samples collected
from FIV-infected queens. Reactivity to the
immunodominant p24 is indicated. Arrows identify strips
tested with sera collected at week 8 p.i. or at the terminal
bleed. ........................................................................................... 37

3.6.

CrFK cells from Virus Neutralization Assays. Infected cells
were incubated in a high dilution of early term AF (A), high
dilution of late term AF (C), and cells were untreated with the
cooresponding fluids (B and D). ................................................... 39
vii

3.7.

Syncytium reduction assays using AF or serum from cat 0866.
The mean number of syncytia produced in FIV-infected CrFK
cells treated with diluted AF (A) or serum (B) is shown as
bars bracketed by the standard error of the mean. P ≤ 0.05
were significant. ............................................................................ 40

3.8.

Syncytium reduction assays using AF or serum from cat 6062.
The mean number of syncytia produced in FIV-infected CrFK
cells treated with diluted AF (A) or serum (B) is shown as
bars bracketed by the standard error of the mean. P ≤ 0.05
were significant. ............................................................................ 42

3.9.

Syncytium reduction assays using AF or serum from cat 1126.
The mean number of syncytia produced in FIV-infected CrFK
cells treated with diluted AF (A) or serum (B) is shown as
bars bracketed by the standard error of the mean. P ≤ 0.05
were significant. ............................................................................ 44

3.10.

Syncytium reduction assays using AF from cat 9674A. The
mean number of syncytia produced in FIV-infected CrFK
cells treated with diluted AF is shown as bars bracketed by
the standard error of the mean. P ≤ 0.05 were significant. ........... 46

3.11.

Syncytium reduction assays using AF from cat 9810A. The
mean number of syncytia produced in FIV-infected CrFK
cells treated with diluted AF is shown as bars bracketed by
the standard error of the mean. P ≤ 0.05 were significant. ........... 48

3.12.

Syncytium reduction assays using AF from cat 9806B. The
mean number of syncytia produced in FIV-infected CrFK
cells treated with diluted AF is shown as bars bracketed by
the standard error of the mean. P ≤ 0.05 were significant. ........... 50

viii

CHAPTER I
REVIEW OF PERTINENT LITERATURE
Primary infection by FIV is marked by an acute phase, lasting 1-4 weeks.
This phase may be clinically silent in some individuals and/or may be manifested
as depression, anorexia, neutropenia, and other symptoms. The acute phase
can lead to major life-threatening bacterial infections. The acute phase is
followed by the asymptomatic phase in which symptoms are absent and the virus
may appear to have completely disappeared, since the infection sometimes
remains silent for years. Some accompanying symptoms are depression,
anorexia, acute diarrhea, dermatitis, gingivitis, and upper respiratory problems.
The persistent generalized lymphadenopathy phase is characterized by swelling
of the cat’s lymph nodes and infrequent, very vague symptoms, including fever,
anorexia, weight loss, and sometimes nonspecific behavioral changes. During
the AIDS-related complex (ARC) phase, the infected cats show chronic
secondary infections of the oral cavity, upper respiratory tract, and other body
sites. These infections are usually caused by various pathogens including
Pseudomonas sp., Microsporum canis, and Steptococcus canis. Eventually,
infected cats progress to feline AIDS, including opportunistic infections, cancer,
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and neurological disorders, usually leading to death of the animal (Bendinelli et
al., 1995).

FIV: A Model for HIV
The FIV-infected cat is used as a small animal model for the study of
pathogenesis and transmission of HIV infections (English et al., 1993). FIV and
HIV share similar biological, genetic, and structural characteristics. As in other
lentiviruses, the FIV genome is composed of three large open reading frames
(gag, pol, env), that encode internal structural proteins, viral enzymes, and
envelope glycoproteins, respectively. Additional overlapping genes include vif,
rev, and ORF (tat in the HIV genome), which encode accessory proteins that
function in regulating or optimizing viral replication. HIV encodes three additional
accessory genes not found in the FIV genome, vpr, vpu, and nef (Bendinelli et
al., 1995). FIV infection progresses in phases similar to those identified in HIV
pathogenesis, beginning with a primary state of infection and progressing a more
severe, often fatal phase. An essential difference between HIV and FIV is their
use of receptors for binding the host cell. The primary receptor for HIV is CD4,
whereas the primary receptor for FIV is CD134, an activation marker on T cells
(Willett et al., 2006). However, the viruses share the same co-receptor, CXCR4,
a chemokine receptor typically found on activated T cells (Willett et al., 1997b).
Both viruses infect T lymphocytes and macrophages, causing syncytium
formation (Brunner & Pedersen, 1989), and an immunocompromised condition
that results from lymphocyte apoptosis and CD4+ T cell depletion (Bendinelli et
2

al., 1995; Willett et al., 1997a). FIV tropism is broader than that of HIV, infecting
CD4 and CD8 lymphocytes, monocytes-macrophages, astrocytes, and microglial
cells. FIV infection of CD4+, CD8+, and a variety of interleukin-2 dependent and
independent T cell lines, results in apoptosis, ballooning of cells, or syncytium
formation (Bendinelli et al.,1995). English et. al. (1993) discovered that the FIV
provirus was also present in T-null cell populations. These T-null cells include
natural killer cells and IL-2 activated LAK cells. FIV infection, like HIV, reduces
expression of the CD4 antigen in CD4+ T cells.

Mother to Child Transmission (MTCT) and Pregnancy Outcome
Globally, 1.5 million children are infected with HIV annually, and 33.3% of
these children will die from AIDS (UNAIDS/WHO, 2000). At least 91% of
pediatric AIDS cases are a result of perinatal transmission occurring either in
utero, during delivery, or lactogenically (CDC, March 2007). Mother to child
transmission of HIV-1 occurs in 14 to 48% of infected, pregnant women
worldwide (John & Kreiss, 1996) with a range of 13 to 32% in the United States
(Dabis et al., 1993). Anti-retroviral drug therapy has reduced vertically
transmitted infections in developed countries by reducing maternal viral load
(Kind et al., 1998; Mandelbrot et al., 1998); however, cost and availability limit
access to anti-retroviral drugs for many women in impoverished nations (Newell,
2000).
Due to a high virus load in saliva, the major route of natural transmission
of FIV is through bite wounds, and therefore, free-roaming toms are the most
3

frequently infected populations. Saliva contains free virus, as well as a high
content of virus infected cells and free cellular debris (Bendinelli et al., 1995).
Seminal transmission (Lunghi et al., 2007) was demonstrated by detection of FIV
gag protein expression in peripheral blood leukocytes weeks after artificial
insemination of queens (Jordan et al., 1996). While the frequency of sexual,
lactogenic, and natural transplacental transmission remains unclear, vertical
transmission among experimentally-infected queens is very efficient and strain
dependent (Bendinelli et al., 1995). O’Neil et al (1996) reported 71% infection of
the offspring delivered from queens who were chronically infected with either
FIV-B-2542 or FIV-AB-2771, accompanied by a low CD4 cell count in 6 of the 19
FIV-infected kittens. Rogers and Hoover (2002) concluded that queens infected
with FIV-C-Pgmr strain produced offspring in which 92% of the fetuses and all
placentas were infected with the virus, while queens infected with a second
strain, FIV-B-2542, produced offspring in which 60% of the fetuses and 96% of
placentas were infected. The rate of transplacental infection increases with
gestational age, with fetal infection prevalences of 0%, 5%, 38%, and 60% at 3
weeks, 5 weeks, 7 weeks, and 9 weeks gestation, respectively (Rogers &
Hoover, 2002). Weaver et al (2005) reported 95% fetal infection at 8 weeks
gestation when queens were infected with FIV-B-2542 prior to breeding, and viral
infection was accompanied by a high rate of fetal non-viability. We recently
reported fetal infection in 14 of 14 representative placentas and 12 of 14
accompanying fetuses by week 3-4 gestation. In this study, uninfected queens
produced 41 viable and 2 non-viable fetuses, whereas the infected queens
4

produced 21 viable and 6 non-viable fetuses. The litter size was reduced and
reproductive failure was significantly higher in FIV-infected queens when
compared to control cats (Boudreaux et al., 2009).

Viral Contamination of Amniotic Fluid
The amnion, a fluid-filled membrane surrounding the fetus, provides
buoyancy to protect against shock, provide freedom of movement, and allow
symmetrical development. Infection of amniotic fluid by various viruses has been
reported. Enders et. al reported that parvoviral DNA was detected in 20% (12 of
60) of the human amniotic fluid samples from fetuses with hydrops, anemia, or
isolated effusion. The viral load in the positive cases exceeded a concentration
of 107 copies/mL (Enders et al., 2009). The amniotic fluid of 92 Iranian women
undergoing cesarean section was evaluated for the presence of human
cytomegalovirus (HCMV) DNA sequences. HCMV was detected in 4 of 15
amniotic fluid samples (Ziyaeyan et al., 2007). In another study using nested
PCR to detect viral DNA, HCMV load was detected at a higher concentration in
amniotic fluid than in plasma (Gouarin et al., 2002). Using real-time PCR, HCMV
was detected in 100% of amniotic fluid samples from the patients between 8-38
weeks of gestation whose fetuses were shown to have developmental
abnormalities by ultrasonography (Gouarin et al., 2002). Contamination of
amniotic fluid with HIV was demonstrated in infected mothers (Mundy et al.,
1987). Jaspan et. al (2004) detected the p24 antigen in the amniotic fluid of 8 of
10 HIV-1 infected mothers at delivery. In a study by Mohala et. al (2005), HIV
5

contamination of amniotic fluid did not occur by 38-40 weeks of gestation in
women undergoing anti-retroviral therapy. Rupture of the amniotic membrane
during vaginal delivery is considered a likely mode of HIV contamination of these
fluids from the cervix. Thus, delivery by cesarean section minimizes the potential
for amniotic fluid contamination and reduces the risk of fetal exposure to the
virus.

Immunological and Neutralizing Responses
The replication of HIV and FIV is restricted by both cell-mediated and
humoral immune responses in the infected host. Cats acutely infected with FIV
for as little as three to six weeks develop virus-specific antibody responses.
These antibodies limit the infection both in vitro and in vivo, block cell-associated
and cell-free infection, and prevent virus replication in previously-infected cats.
Burkhardt et. al reported that the passage of cell-free FIV across a mucosal
surface can be hindered by IgG in plasma elicited during early FIV infection
(Burkhard & Hoover, 2005).
FIV epitopes were shown to stimulate neutralizing antibodies which
suppress infection (Tozzini et al., 1993). These antibodies were sometimes
evident at two to six weeks after infection and persisted during a three year
period of observation (Bendinelli et al., 1995). Neutralizing antibodies in the sera
of HIV-1-infected pregnant women were proven to reduce the risk of vertical
transmission (Scarlatti et al., 1993). Kamara et al (2005) reported that at a low
plasma dilution (10-1), maternal antibodies were capable of reducing HIV-1
6

infection, whereas at a higher dilutions (10-3 and 10-5), the antibodies enhanced
viral replication. Parren et. al (2001) discovered that HIV-1 isolates were
neutralized by the sera collected from pregnant women of long-term infected
patients. Barin et al (2006) showed that 79% of 28 serum samples had
neutralizing activity against HIV-1.
Jaspan et al (2004) reported that the amniotic fluid of HIV-infected
women contained a higher neutralizing antibody titer than plasma and was
capable of reducing infection. The concentration of anti-HIV-1 antibody was
similar between amniotic fluid and plasma; however the total concentration of
antibodies in amniotic fluid was significantly lower than in plasma. In the SIVinfected rhesus macaque model, animals expressed significantly higher ratios of
SIV p27-specific antibodies in the amniotic fluid than plasma. These studies
indicate that amniotic fluid may be more important in protecting the fetus from
vertical transmission, via neutralization, than is plasma. The amniotic fluid from
infected humans possessed the ability to block HIV infection, but the extent of the
neutralization activity could not be determined due to prior treatment of the
patient with the anti-retroviral drug zidovidine. The amniotic fluid of the majority
of the SIV-infected macaques, in the absence of retroviral drugs, contained
neutralizing antibodies to SIV. While a higher antibody titer to HIV was found in
amniotic fluid than serum of both HIV-infected pregnant women and SIV-infected
rhesus macaques (Jaspan et al., 2004), this type of comparison has not been
conducted among FIV-infected cats.
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Significance and Purpose of Study
The role that amniotic fluid play in MTCT of HIV remains unclear. There is
no clear correlation between the presence of virus in amniotic fluids and fetal
infection, nor does the presence of virus neutralizing antibodies in AF eliminate
vertical transfer (Bal et. al., 1996; Dickerson et, al., 2006; Husson et. al., 1995). It
is difficult to address this enigma in humans because of difficulty in obtaining AF
while membranes are intact, prior to their contamination by maternal blood. In
addition, most infected women are treated with anti-retroviral drugs which
artificially reduce virus load in these fluids. We used the FIV-infected cat model
to address this question because this system is an accepted small animal model
for lentivirus pathogenesis and transmission, because the virus is efficiently
transmitted in utero under experimental conditions. In addition, the cats typically
produce multiple offspring/litter, allowing the opportunity to obtain multiple
samples from the same cat. We obtained AF and sera from early- and late-term
pregnancies from queens that produced very high rates of fetal infection. AF was
evaluated for viral load by measuring viral RNA and p24 antigen. AF and
corresponding sera were tested for FIV-specific antibody by ELISA assays, and
randomly-selected AF were examined for virus neutralizing activity using a
syncytium reduction assay. Herein, we report that FIV was not detected in AF,
but both AF and sera were positive for FIV-specific antbody. It is interesting that
early gestation AF and one corresponding serum had VN activity, while late-term
AF did not. The data suggest that the amniotic fluids do not play an important
role in fetal infection.
8
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CHAPTER II
ANALYSIS OF AMNIOTIC FLUID AND MATERNAL SERA FROM FELINE
IMMUNODEFICIENCY VIRUS (FIV)- INFECTED CATS FOR
VIRUS-SPECIFIC ANTIBODY AND VIREMIA

Abstract
FIV, a lentivirus related to HIV, produces a syndrome in the infected cat
that closely parallels that of the HIV-infected human. Thus, the FIV-infected cat
is used as a small animal model of HIV pathogenesis. Both viruses are vertically
transmissible, resulting in fetal infection and increased reproductive failure.
Infected amniotic fluids (AF) are a potential source of fetal infection. Therefore,
virus-neutralizing (VN) antibodies, which may be present in AF, may play a role
in limiting fetal infection. We hypothesized that amniotic fluids may be
contaminated with FIV and contain VN antibodies. Fetuses were delivered from
FIV-infected queens by cesarean section either at week 3-4 or week 8 of
gestation. AF were aseptically aspirated from intact fetal membranes and frozen.
Analysis of fetal RNA or DNA for the presence of FIV revealed a very high rate of
fetal infection. All AF were tested for viral p24 antigen using a commercial ELISA
kit and for viral RNA using real time RT-PCR. FIV was below the level of
detection by both assay methods. Randomly-selected AF from early and late
13

gestation were tested for anti-viral antibody using two types of commercial ELISA
kits. We detected anti-FIV p24 antibody in most early- and late-term AF (63%
and 61%, respectively). Corresponding sera from early-term queens were tested
for anti-viral antibody using Western Blot analysis and a commercial ELISA kit.
The serum samples were positive for the FIV-specific antibody by Western blot,
however the commercial ELISA was less sensitive (33% positive). Randomlyselected AF and sera were further evaluated for neutralizing antibody activity by
performing a syncytium-reduction assay in FIV-infected Crandell feline kidney
(CrFK) cells. Medium containing serially-diluted AF or maternal sera was added
to FIV-infected CrFK cells in 24 well plates; the cells were incubated one week.
The cells were stained with Giemsa, and syncytia were counted. The number of
syncytia was significantly decreased in three early-term AF and a parallel serum,
but not the late-term AF. Interestingly, although AF contained no detectable virus
but did contain VN activity, maternal-fetal infection occurred frequently. Thus, AF
appears to play no appreciable role in FIV vertical transmission.

Introduction
Globally, 1.5 million children are infected annually with HIV, and 33.3% of
these children will die from AIDS (UNAIDS/WHO, 2000). At least 91% of
pediatric AIDS cases are a result of perinatal transmission occurring either in
utero, during delivery, or lactogenically (CDC, March 2007). MTCT of HIV-1
occurs in 14 to 48% of infected, pregnant women worldwide (John & Kreiss,
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1996) with a range of 13 to 32% in the United States (Dabis et al., 1993) in the
absence of anti-retroviral therapy.
The role of amniotic fluids (AF) in HIV mother-to-child (MTCT)
transmission remains unresolved. HIV contamination of AF has been reported
(Jaspan et al., 2004; Mundy et al., 1987). Virus was detected in 28% of 101
oropharyngeal or gastric aspirates from newborns from the French Perinatal
Cohort Study of MTCT, revealing frequent oral exposure to the virus in utero
(Mandelbrot et al., 1999). On the other hand, HIV contamination of amniotic fluid
did not occur by 38-40 weeks of gestation in a group of women undergoing antiretroviral therapy, but rupture of the amniotic membrane during vaginal delivery
may allow HIV contamination of these fluids from the cervix (Mohlala et al.,
2005). Cesarean delivery minimizes the potential for amniotic fluid contamination
and reduces the risk of fetal exposure to the virus.
Numerous investigators reported HIV-1 neutralizing antibody in maternal
serum or plasma (Barin et al., 2006; Kamara et al., 2005; Parren et al., 2001).
Neutralizing antibodies in the sera of HIV-1-infected pregnant women reduced
the risk of vertical transmission (Scarlatti et al., 1993). Likewise, FIV epitopes
were shown to stimulate neutralizing antibodies which suppress infection (Tozzini
et al., 1993). These antibodies were sometimes evident at two to six weeks after
infection and persisted during a 3 year period of observation (Bendinelli et al.,
1995).
HIV-1 and SIV-specific antibodies were detected in both plasma and
amniotic fluids from their respective host species. However, AF obtained from
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HIV-infected women could not be used in virus neutralization assays because
they were collected from women who had been treated with zidovudine during
pregnancy. The potential presence of the drug in AF complicates the
interpretation of the role of VN antibodies in reducing viral replication. This
complication limits the usefulness of AF collected from most infected women in
the U.S. or other developed nations who usually receive anti-retroviral drugs
during pregnancy. Using samples collected from SIV-infected rhesus macaques
which had not been treated with anti-retroviral drugs, the AF of five of six animals
contained neutralizing antibodies to SIV. The one animal whose AF did not
contain VN activity produced an infected infant, suggesting that the VN
antibodies protected the infant.
We obtained AF and sera from early- and late-term pregnancies from FIVinfected queens that produced very high rates of fetal infection. AF were
evaluated for viral load by measuring viral RNA and p24 antigen. AF and
corresponding sera were tested for FIV-specific antibody by ELISA assays, and
randomly-selected AF were examined for virus neutralizing activity using a
syncytium reduction assay. Herein, we report that FIV was not detected in AF,
but both AF and sera were positive for FIV-specific antbody. It is interesting that
early gestation AF and one corresponding serum had VN activity, while late-term
AF did not. The data suggest that the amniotic fluids do not play an important
role in fetal infection in the FIV-infected cat.
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Materials and Methods
Animals and Virus
All cats used in this study were reproductively-mature, specific pathogenfree (SPF) animals obtained from a commercial cattery. Groups of ten cats were
inoculated with a feline plasma pool containing FIV-B-2542 (provided by E.A.
Hoover, Colorado State University); groups of ten cats were uninoculated to
serve as negative controls. FIV infection in the inoculated group was confirmed
using PCR and serology, then the cats were allowed to naturally breed with SPF
males. Pregnancies were confirmed by ultrasonography. Pregnancies of
infected and control groups were terminated at week 3-4 (early gestation study)
or week 8 (late gestation study) by cesarean section.
Collection of Amniotic Fluid and Serum
The amniotic fluid within each fetal membrane was collected by puncturing
the membrane with a 21 g needle and aspirating into a syringe. Caution was
taken to prevent infected maternal blood from contaminating the amniotic fluid.
Fetuses, placentas, amniotic fluids, and maternal blood (serum, plasma,
leukocyte DNA and RNA), collected at each delivery, were frozen at -80ºC until
needed. Whole blood was drawn at biweekly to monthly intervals until delivery
for the collection of serum, plasma, and peripheral blood lymphocytes.
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FIV Antibody Detection using SNAP FIV/FeLV ELISA
Infected amniotic fluid samples were selected randomly for analysis using
the SNAP FIV/FELV ELISA kits (IDEXX Laboratories; Westbrook, ME) to detect
FIV antibody in amniotic fluid. Briefly, three drops of amniotic fluid were added to
a solution containing anti-feline IgG conjugated to horseradish peroxidase, and
the mixture was added to the SNAP device. The device was “snapped” to allow
interaction of captured antibody complex with the enzyme substrate. AF that
contained FIV-specific antibody produced a blue dot in the appropriate position
on the membrane.
FIV Antibody Detection using the Petchek FIV Antibody Test Kit
FIV antibody in all amniotic fluid and the corresponding serum samples
were determined using the PetChek FIV Antibody Test Kit (Idexx Laboratories;
Westbrook, ME). Briefly, this sandwich ELISA assay utilized a 96-well microtiter
plate, coated with FIV antigen. Samples from FIV-infected cats were added to
the well, along with the appropriate positive and negative controls included in the
kit. The samples were incubated with the horseradish peroxidase (HRPO)
labeled FIV antigen. The preparation was incubated and washed to remove
unbound antigen, then the enzyme substrate/chromagen solution was added.
Color development was detected using an ELISA plate reader at a wavelength of
650 nm. Positive reactions were subjected to a confirmatory procedure. Color
development was proportional to the amount of FIV in the sample. Sample to
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positive ratios (S/P) were determined according to kit instructions. A threshold
value (0.5) was set, and all S/P ratios above 0.5 were considered positive.
Whole Virus Purification
Supernatant and cell lysate collected from FIV-infected T cell cultures
(MCH 5-4, kindly provided by Dr. John Elder) were centrifuged at 11,750 x g in a
GSA centrifuge at 4°C for 20 min to remove cellular debris. The clarified
supernatant was centrifuged at 23,000 x g for 90 min at 4°C using an SW27 rotor
and a Beckman L8-80M Ultracentrifuge. The supernatant was discarded, and the
tubes were inverted and allowed to drain. Pellets containing virus were
resuspended in 200 ml of PBS and stored at -80°C.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
The 12% polyacrylamide gels used for the separation of proteins were
composed of 12% acrylamide/bis, 1.5 M Tris-HCl (pH 8.8), 0.5 M Tris-HCl (pH
6.8), 10% SDS, 10% ammonium persulfate, and TEMED. The stock virus was
diluted 1:4 in sample reducing buffer (0.5 M Tris-HCl (pH 6.8), glycerol, 10%
SDS, 5% 2-mercaptoethanol, 1% bromophenol blue). Electrophoresis was done
using the Mini Protein II system (Bio-Rad Laboratories, Hercules, CA), according
to standard procedure (Laemmli, 1970). Electrophoresis was conducted at 100
volts for ~1 h, followed by transfer of proteins to nitrocellulose membranes
(Micron Separations Inc., Westborough, MA). We performed the transfer using
the Towbin buffer (25mM Tris, 192 mM glycine, 20% methanol, pH 8.3) and a
semi-dry transfer apparatus (BioRad Laboratories; Hercules, CA) at 15 volts for
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0.5h. Proteins on the membrane were visualized by soaking the membrane for 5
min in Ponceau S, followed by destaining in multiple changes of distilled water.
The nitrocellulose was vertically cut into strips for use in Western blotting.
Western Blot Procedure
The nitrocellulose strips containing immobilized protein were incubated for
at least 2 h in 5% Blotto (5 g Carnation non-fat dry milk in Tris-saline tween
buffer) (TS-T; 10 mM Tris, 15 mM NaCl, 0.05%, pH 8.6) to prevent nonspecific
binding of antibody to the nitrocellulose. The sample sera, along with a positive
and negative control, was added to each well and allowed to incubate overnight.
After removing the blotto/serum mixture and washing the strips, the secondary
antibody, goat anti-cat IgG peroxidase (ICN Pharmaceuticals, Aurora, Ohio) was
diluted (1:1000) and added to each well, and the strips were incubated 1-2 h.
After washing the strips, an enzyme substrate/chromagen solution (0.02 g 4chloronaphthol dissolved in 5 ml of methanol, 0.05 M Tris pH 6.8, and 12 μl
H2O2) was added. The reaction is stopped by rinsing with distilled water.
CrFK Cell Culture and Infection
Crandell Feline Kidney cells (CrFK) were cultured in complete CrFK
medium containing Minimum Essential Medium (Gibco), 1.5 g/L sodium
bicarbonate, 1.0 mM sodium pyruvate, 1.0 mM non-essential amino acids, 10%
antibiotics, and 10% fetal calf serum. Cells were infected with FIV-B-2542 using
infectious pooled plasma collected from previously-infected cats. The inoculum,
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diluted 1:10 in medium, was added to the cell monolayer and incubated for 1 h at
37°C. The inoculum was removed and replaced with complete culture medium.
Virus Neutralization Assay (Syncytium Reduction Assay)
The VN was done according to a modification of the procedure of Jaspan
et al (2004). Six samples of amniotic fluid and the corresponding serum
samples, positive for FIV antibodies, were heat inactivated at 56ºC for 30 min.
Infected Crandell Feline Kidney (CrFK) cells were added to 12 wells and noninfected CrFK cells were added to 8 wells (density 5 x 104 cells/well) of a multiwell plate, according to the following diagram (Figure 2.1). Amniotic fluid samples
were diluted in a four-fold series, mixed with the cells, and incubated in a 5%
CO2 incubator at 37ºC for 7 days. Following incubation, these reaction mixtures
were removed; the cells were fixed in methanol and stained with 5% Giemsa.
Wells were microscopically observed at 40X magnification for the development of
syncytia.
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Triplicate cultures of
each dilution

1:16

Dilutions

1:64

1:256

No
Fluid
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FIV+, ‐Fluid

FIV ‐, + Fluid
Figure 2.1 Virus Neutralization Assay Design

Quantification of FIV Antigen in Amniotic Fluid
FIV load in amniotic fluid and serum samples was determined using the
PetChek FIV Antigen Test Kit (Idexx Laboratories). Briefly, this sandwich ELISA
assay used a 96-well microtiter plate, coated with monoclonal antibody specific
for FIV p24. Samples from FIV-infected cats were added to the wells, along with
a serum and amniotic fluid sample from a control cat. Appropriate positive and
negative controls, included in the kit, were used as well. After the incubation and
washes, the second monoclonal antibody to p24, labeled with horseradish
peroxidase, was added. The reaction was incubated and washed to remove
unbound antibody, then the enzyme substrate/chromagen solution was added.
Color development was detected using an ELISA plate reader at a wavelength of
650 nm. Positive reactions were subjected to a confirmatory procedure. Color
development was proportional to the amount of FIV in the sample.
RNA Extraction
RNA was extracted from the amniotic fluid using the QIAamp Viral RNA
Mini Kit (Qiagen). RNA concentration was measured on NanoDrop 1000
(Thermo Scientific, Waltham, MA) and stored in -80ºC until needed.
Quantification of FIV RNA using Real-Time Reverse Transcriptase (RT) PCR
Real time TaqMan primers and probes targeting the FIV gag gene and βactin (housekeeping gene) were obtained commercially (MWG Biotech, Inc.,
High Point, NC). The primer and probe sequences and 5’ and 3’ probe labels are
shown in Table 2.1. The 25 μL PCR mixtures contained 6 μL standard or sample,
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12.5 μL of qRT-PCR Thermoscript reaction mix (Invitrogen), 0.5 μL Thermoscript
Taq (Invitrogen), 1 μL β-actin forward and reverse primers (10 pmole/ μL), 1 μL
of FIV gag forward and reverse primers (10 pmole/μL), and 1 μL β-actin and FIV
gag probe (1 pmole/μL). Serial, 2-fold dilutions of viral RNA (1:2 to 1:64) were
used to generate a standard curve. Samples and standards were analyzed in
triplicate on a 96 well plate using an iCycler (Bio-Rad). The following thermal
cycling parameters were used: 3 min at 95ºC, 40 cycles at 95ºC for 30 sec, and
30 sec at 60ºC.
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Table 2.1 Oligonucleotides used for real-time RT-PCR gene expression analysis
Targeted genes
and Gen Bank
accession
number

Sequence (5’ → 3’)

Purpose

5’
Label

Gag

5’‐GTATGATCGTACTCATCCTCCTGAT‐3’
5’‐TCTACATTGCATTCTGGCTGGT‐3’
5’‐AGACCACTGCCCTACTTCACTGCCG‐3’

Forward
Reverse
Probe

____
____
FAM

Β‐actin
AB051104

5’‐GACTACCTCATGAAGATCCTCACG‐3’
5’‐TCTCCTTGATGTCACGCACAATT‐3’
5’‐ACAGTTTCACCACCACCGCCGAGC‐3’

Forward
Reverse
Probe

____
____
HEX

Target probe labels: 5’ FAM (6-carboxyfluorescein), 3’ TAMRA (6carboxytetramethylrhodamine), 5’ HEX (hexachloro-6-carboxyfluorescein)
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Statistical Analysis
Statistical analysis of FIV load and antibody levels in amniotic fluid was
completed using single-factor ANOVA at the 95% confidence level.

Results
I. Viral Load and FIV-specific Antibody in Amniotic Fluids (AF)

Viral Load and FIV-specific Antibody Detection in Early-term AF Samples
Early-term amniotic fluid samples were tested for FIV load and FIVspecific antibody (Table 3.1). The majority of the samples were tested for FIV
p24 antigen using the Petchek Ag Test kit. All samples were negative, indicating
that virus was either absent or below the level of detection in AF. One sample
from each queen was tested for viral RNA using real time RT-PCR. No viral RNA
was detected in any of the samples, confirming the results of the p24 antigen
assay. Using SNAP ELISA kits to detect FIV-specific IgG in nine randomlyselected AF samples, six samples were strongly positive (5111B, 0866A, 0866C,
0866E, 1893C, and 1126D) one was weakly positive (6062A), and two were
negative (8035B and 6062B) (Figure 3.1).

Viral Load and FIV-specific Antibody in Late-term AF Samples
Late-term amniotic fluid samples were tested for FIV load and FIV-specific
antibody (Table 3.2). All samples were tested for FIV p24 antigen using the
Petchek Ag Test kit. All samples were negative, indicating that virus was either
absent or below the level of detection in AF. One sample from each queen was
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tested for viral RNA using real time RT-PCR. No viral RNA was detected in any
of the samples, confirming the results of the p24 antigen assay. Using SNAP
ELISA kits to detect FIV-specific IgG in eight randomly-selected AF samples, two
samples were strongly positive (9745A and 9806A), four samples were weakly
positive (9674A, 9810A, 13226E, and 9809A), and two samples were negative
(9730A and 13226B).
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Table 3.1 Viral Load and IgG Detection of the Early Term Amniotic Fluid
Samples

Infected Cat #
O326
8035 A
8035 B (Arr)
8035 C (Arr)
8035 D (Res)
5111 A
5111 B*
0866 A
0866 C
0866 E
0866 F
1893 A
1893 C
6062 A
6062 B
6062 C
1126 D

Real Time PCR
negative
ND
ND
ND
negative
negative
ND
ND
ND
negative
ND
negative
ND
ND
negative
ND
negative

Ag ELISA
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
N/A

FIV‐specific
IgG
ND
ND
negative
ND
ND
ND
strong +
strong +
strong +
strong +
ND
ND
strong +
very weak +
negative
ND
strong +

Fetal Infection
weakly +
negative
negative
positive
ND
weakly +
weakly +
positive
ND
ND
ND
weakly +
ND
weakly +
weakly +
ND
ND

Note: (*) blood contamination; (ND) not done; (Arr) amniotic fluid from arrested
fetus; (Res) amniotic fluid from arrested fetus
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Table 3.2 Viral Load and IgG Detection of the Late Term AF Samples

Infected Cat #
9674 A
9813 A
9810 A
9730 A
9730 B
9730 C Res
9730 D Res
13226 A Arr
13226 B Arr
13226 C Arr
13226 D Arr
13226 E Arr
9745 A
9745 B Res
9745 C Res
9745 D
9745 E Res
9745 F
9806 A
9806 B
9809 A

Real Time
PCR
negative
negative
negative
ND
ND
negative
ND
ND
ND
ND
negative
ND
negative
ND
ND
ND
ND
ND
negative
ND
negative

Ag ELISA
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative
negative

FIV‐specific IgG
weak +
ND
weak +
negative
ND
ND
ND
ND
negative
ND
ND
weak +
strong +
ND
ND
ND
ND
ND
strong +
ND
weak +

Fetal
Infection
positive
positive
positive
positive
positive
positive
positive
positive
positive
positive
positive
positive
negative
positive
positive
positive
positive
positive
positive
positive
positive

(Arr) amniotic fluid from arrested fetus; (Res) amniotic fluid from arrested fetus
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1126 D

0866 A

0866 E

9806 AA

9810 AA

9745 A

9809 AA

Figure 3.1 SNAP ELISAs for Early and Late Term AF Sample
Note: 8035 B, 5111B, 0866 E, 1893C, 9674A, 9730A, and 13226 B are
not shown.
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II. Relative Level of FIV-specific Antibody in AF

Relative FIV-specific Antibody Levels for Early-term AF
The sample-to-positive (S/P) ratios of seroreactivity to FIV p24 for all
early-term AF samples, determined using the FIV Petchek Antibody test kit, are
shown in Figure 3.2. Samples with an S/P ratio more than the 0.5 threshold were
considered positive. Ten of the sixteen samples (63%) had a ratio higher than
0.5, and thus, were positive for FIV-specific antibodies.
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Figure 3.2: Relative Levels of FIV-specific Antibody in Early-term AF Samples.
OD of 650 nm were determined for each sample and controls
(included in kit), and sample to positive (S/P) ratios were calculated.
The 0.5 S/P indicates the positive/negative threshold for antibody
detection. All S/P ratios above 0.5 were considered positive.
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Relative FIV-specific Antibody Levels for Late-term AF
The sample-to-positive (S/P) ratios of seroreactivity to FIV p24 for all
early-term AF samples, determined using the FIV Petchek Antibody test kit, are
shown in Figure 3.3. Samples with a S/P ratio over the 0.5 threshold were
considered positive. Eleven of the eighteen samples (61%) had a ratio higher
than 0.5, and thus, were positive for FIV-specific antibodies. Two of the six FIVinfected queens produced FIV seropositive AF for all fetal membranes. Only one
AF sample from queen 13226 was FIV seropositive out of the five tested. These
results reveal serological variability even within single queens.
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Figure 3.3: Relative Levels of FIV-specific Antibody in Late –term AF Samples.
OD 650 nm were determined for each sample and controls (included
in kit), and sample to positive (S/P) ratios were calculated. The 0.5
S/P indicates the positive/negative threshold for antibody detection.
All S/P ratios above 0.5 were considered positive.
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Comparisons of FIV Seroreactivity in Serum from Early Infection vs. Termination
The results of ELISA to detect FIV-specific antibody in serum collected
from infected queens during early infection (week 8) and at termination are
shown in Figure 3.4. Only two animals were seropositive using this assay (8035
and 5111), both of whom had higher antibody levels at week 8 p.i. The western
blot analysis of longitudinal serum samples identified seroreactivity to FIV p24,
the major immunodominant viral protein in all animals. All animals were strongly
seroreactive by termination at 21-25 weeks p.i., and four of six animals were
strongly positive by the week 8 p.i. bleed. Only animals 1893 and 1826 produced
a weak serological response at week 8 p.i.
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Figure 3.4: Relative Levels of FIV-specific Antibody in Serum Samples. OD 650
nm were determined for each sample and controls (included in kit),
and sample to positive (S/P) ratios were calculated. The 0.5 S/P
indicates the positive/negative threshold for antibody detection. All
S/P ratios above 0.5 were considered positive.
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Figure 3.5: Western blot analysis of longitudinal serum samples collected from
FIV-infected queens. Reactivity to the immunodominant p24 is
indicated. Arrows identify strips tested with sera collected at week 8
p.i. or at the terminal bleed.
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III. Syncytium Reduction with AF and Terminal Serum Samples

Early Pregnancies
Figure 3.6 is representative of the cytopathic effect that was observed with
the syncytium reduction assay. In the presence of early-(A) or late-term (C) AF,
syncytia were reduced or not evident in FIV-infected CrFK cells. However, in the
absence of treatment with AF (B and D), syncytia were prominent in infected
CrFK cells.
The results of the syncytium reduction assay for queen 0866 AF and
terminal serum sample are shown in Figure 3.7. The mean syncytium counts for
triplicate cultures of FIV-infected CrFK cells treated with AF or serum dilutions
are graphed. For the AF (Figure 3.7A), the mean number of syncytia was
significantly higher (p=0.04) at the 1:64 dilution of AF than the 1:16 dilution.
Likewise, a significantly higher number of syncytia developed in cultures that
were untreated with AF than those treated with the lowest dilution (p= 0.03). The
data show that AF reduced viral replication and indicate that VN antibodies were
present in AF from this animal. For the serum assay (Figure 3.7 B), mean
syncytia were reduced with increased dilution from 1:16 to 1:256 (p=0.02) and
1:64 to 1:256 (p=0.02), while the 1:16 dilution yielded a very similar number of
mean syncytia as the untreated cells. These data are opposite the expected
results and are difficult to interpret.
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Syncytia

A

B
Syncytia
Syncytia

C

D

Figure 3.6: CrFK cells from Virus Neutralization Assays. Infected cells were
incubated in a high dilution of early term AF (A), high dilution of late
term AF (C), and cells were untreated with the cooresponding fluids
(B and D).
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Figure 3.7: Syncytium reduction assays using AF or serum from cat 0866. The
mean number of syncytia produced in FIV-infected CrFK cells treated
with diluted AF (A) or serum (B) is shown as bars bracketed by the
standard error of the mean. P ≤ 0.05 were significant.
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The results of the syncytium reduction assay for queen 6062 AF and
terminal serum sample are shown in Figure 3.8. In comparison to all dilutions,
the mean number of syncytia was significantly higher in cultures untreated with
AF (Figure 3.8 A), with P values of 0.001, 0.008, and 0.03 for AF dilutions of
1:16, 1:64, and 1:256, respectively. None of the cultures treated with AF were
different from each other (p> 0.05). Serum from this animal produced very
similar results with untreated cultures yielding significantly higher numbers of
syncytia than those treated with serum diluted 1:16 (p= 0.02), 1:64 (p= 0.01), and
1:256 (p= 0.02) (Figure 3.8 B). This animal produced VN antibody that was
present in both AF and serum.
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(A)

(B)
Figure 3.8: Syncytium reduction assays using AF or serum from cat 6062. The
mean number of syncytia produced in FIV-infected CrFK cells treated
with diluted AF (A) or serum (B) is shown as bars bracketed by the
standard error of the mean. P ≤ 0.05 were significant.
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The results of the syncytium reduction assay for queen 1126 AF and
terminal serum sample are shown in Figure 3.9. A dose-dependent response in
syncytium reduction was seen. With the exception of the comparison of the 1:16
and 1:64 dilutions, a significant increase in syncytium occurred with decreasing
levels of AF (Figure 3.9 A) . The greatest difference occurred between the
highest concentration of AF (1:16) and lowest concentration of AF (no AF) (p=
0.01). There were no significant differences in mean syncytia between any of the
serum dilutions (Figure 3.9 B). The data reveal VN capability of AF, but not
serum, from this cat.
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(A)

Figure 3.9: Syncytium reduction assays using AF or serum from cat 1126.
The mean number of syncytia produced in FIV-infected CrFK cells
treated with diluted AF (A) or serum (B) is shown as bars
bracketed by the standard error of the mean. P ≤ 0.05 were
significant.
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Late Pregnancies
The results of the syncytium reduction assay for queen 9674A AF are
shown in Figure 3.10. Although the mean number of syncytia appeared to
increase with increasing dilution, the differences did not reach the level of
significance (p> 0.05).
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Figure 3.10: Syncytium reduction assays using AF from cat 9674A. The mean
number of syncytia produced in FIV-infected CrFK cells treated with
diluted AF is shown as bars bracketed by the standard error of the
mean. P ≤ 0.05 were significant.
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The results of the syncytium reduction assay for queen 9810A AF are
shown in Figure 3.11. A clear pattern of syncytium reduction was not evident
because untreated, infected cells produced a similar number of syncytia as those
treated with the highest concentration of AF. Statistical differences were not
detected between any of the comparisons (p>0.05).
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p>0.05

Figure 3.11: Syncytium reduction assays using AF from cat 9810A. The mean
number of syncytia produced in FIV-infected CrFK cells treated
with diluted AF is shown as bars bracketed by the standard error
of the mean. P ≤ 0.05 were significant.
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The results of the syncytium reduction assay for queen 9806B AF are
shown in Figure 3.12. Although the 1:16 dilution produced the lowest mean
syncytium count, this value was not significantly different from the other dilutions
due to wide variability in triplicate cultures at all dilutions.

49

p>0.05

Figure 3.12: Syncytium reduction assays using AF from cat 9806B. The mean
number of syncytia produced in FIV-infected CrFK cells treated with
diluted AF is shown as bars bracketed by the standard error of the
mean. P ≤ 0.05 were significant.
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Discussion
Fetal exposure to HIV in contaminated amniotic fluids is probably a
contributor to the high rate of MTCT infection (14-48%) that occurs globally in the
absence of anti-retroviral therapy (John & Kreiss, 1996). The detection of HIV in
gastric aspirates of neonates indicates oral exposure of the fetus to the virus
through ingestion of contaminated AF (Mandelbrot et al., 1999). The potential
importance of AF as a source of antenatal exposure to HIV is difficult to study in
humans due to limitations in specimen collection and because HIV-infected
women in developing nations are typically treated with anti-retroviral drugs, which
reduce viral load. While the SIV-infected macaque provides an animal model,
the data are limited with this model system due to small numbers of offspring.
The FIV-infected cat model provides a good alternative animal model system due
to the high rate of MTCT that can be achieved under experimental conditions and
the multiple offspring produced by a single queen, which naturally expands the
number of AF samples that can be collected. While this alternative animal model
has been used by us and others to evaluate aspects of lentiviral vertical
transmission, the role of the AF in MTCT in this system has not been extensively
studied.
The purpose of this study was to examine AF samples collected at early
and late stages of gestation to determine whether or not for these fluids play a
role in MTCT. We evaluated the AF for the presence of FIV antigen to determine
viral load, compared FIV-specific antibody reactivity, and measured virus
neutralization activity of AF. We did not detect viral antigen in either early or late
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term AF samples even though corresponding fetuses were infected. Boudreaux
et al (2009), reported 12 of 14 (86%) infected fetuses from FIV- infected queens
at early gestation, using real time RT-PCR to detect viral RNA. Using standard
PCR to detect FIV provirus and serology to detect FIV-specific antibody, Weaver
et al (2005) found 21 of 22 (95%) infected fetuses at late gestation.
Corresponding placentas also were positive (Boudreaux et al., 2009; Weaver et
al., 2005). These data indicate that either virus did not enter the AF fluid during
gestation, or that the viral load was below the limit of detection. Our data are in
agreement with those of Rogers and Hoover (2002) who were unable to detect
FIV RNA in AF from full-term pregnancies in FIV-infected queens. We collected
the AF by needle aspiration prior to opening the fetal membranes, so there was
no possibility of external contamination with maternal blood. Exposure of the
fetus to AF contaminated with maternal blood may occur following prolonged
membrane rupture, providing a means of perinatal HIV infection (Kind et al.,
1998). In contrast, HIV-1 was previously isolated from the AF at 15 week
gestation and 38 week gestation (Mundy et al., 1987; Sprecher S, 1986). Jaspan
et al (2004) detected approximately 5-10 pg/100 μl of HIV-1 p24 antigen in 8 of
10 AF samples collected from full term HIV-infected women, all of whom had
been treated with AZT during months of pregnancy and during labor and delivery.
Despite the fact that all maternal serum samples were FIV seropositive
within 4 weeks p.i. using SNAP ELISA and Western blotting, using the PetChek
FIV Antibody Test Kit ELISA to quantify antibody titer, only 2 of the 6 sera
(animals 8035 and 5111) were positive. Two bleed dates were evaluated using
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this assay, week 8 p.i. and delivery, and the levels of antibody in these two cats
were higher at the earlier time point. The conflicting serological results indicate
that both the SNAP ELISA and Western blot were more sensitive assays than the
PetChek ELISA. Using a commercial ELISA produced by the same company
(IDEXX), Baldinotti et. al (1994) detected FIV-specific antibody reactions in the
sera of cats infected with FIV-M2 (Pisa-M2) and FIV-Pet (Petaluma strain)
collected between 1 and 28 months p.i. Thus, the FIV antibody PetChek ELISA
may have strain-specific sensitivity. The FIV isolate(s) used to prepare antigen
for this kit are unknown to us due to proprietary rights of the manufacturer.
Jaspan et al (2004) compared antibody levels in paired AF and plasma
from SIV-infected rhesus macaques and HIV-1-infected patients. Although
plasma normally has higher immunoglobulin content than AF, they found HIV-1
specific antibodies to be 20 to 700-fold higher in AF after adjusting for
concentration differences. Likewise, SIV p27-specific antibody was higher in AF
than in plasma in macaques, after concentration adjustments were made. We
found the same pattern in the FIV-infected cat at early gestation. Without
adjusting for naturally-higher concentration of total immunoglobulin in plasma, we
found at least one AF from five of six queens to have FIV-specific antibody levels
(based on S/P ratios) ranging from approximately 4 to > 21-fold higher than the
corresponding serum. The two AFs from queen 8035 were both negative for
antibody. Interestingly, these antibody-negative AF were obtained from fetal
membranes of fetuses 8035A and B; both fetuses were negative for viral RNA,
while their placentas were FIV RNA positive (Boudreaux et al., 2009). Cat 8035
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did, however, produce one FIV-infected fetus (8035C), but the AF from that fetus
was not tested in this study. The disparate immunoreactivity that was detected in
different AF from the same queen shows the usefulness of this feline model in
studying fetus-specific pathology without the confounding maternal variables that
naturally arise between individuals in human and non-human primates infected
with their respective immunodeficiency viruses.
Using a syncytium-reduction assay, virus neutralization capability was
detected in three of three AF samples collected from FIV-infected queens at late
gestation, while only one of the corresponding maternal serum samples (6062)
neutralized the virus. While FIV-specific antibody was not detected in serum
from any of the three early-term queens using PetChek ELISA, all animals were
strongly positive by Western blot at corresponding times p.i. However,
seroreactivity to envelope glycoproteins, which express the major neutralizing
epitopes, were not measured by either ELISA or Western blot, so information
gained from these assays is limited. The discrepancy in neutralization between
AF and sera likely corresponds to the greater concentration of FIV-specific
antibody in AF. The same assay failed to detect virus neutralization capability in
AF from any of three FIV-infected queens at late gestation. While the reason for
differences in neutralization capability between early and late gestation is
unknown, AF samples had been stored at -20°C for more than five years, and
some antibody may have degraded. Both sets of animals (early gestation and
late gestation) were infected with a plasma pool obtained from three cats that
were experimentally-infected with FIV-B-2542, rather than cloned virus. Thus,
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antigenic drift, resulting from viral evolution in multiple hosts, may have
generated variation in the immunodominant neutralization epitopes and
consequent variability in dominant neutralizing antibodies. Neutralization escape
mutants evolve frequently during the course of lentiviral infection as a result of
the selective pressure applied by the humoral immune response (Burns &
Desrosiers, 1994; Hussain et al., 1987; Zheng et al., 1997). The FIV-B-2542
plasma pool used to infect CrFK cells in the syncytium reduction assays had
been passed through fewer animals. Therefore, predominant neutralizing
antibodies in both AF and sera may have been directed towards more recentlyevolved variants, diminishing the neutralizing capability of our samples. Others
reported that passage history clearly effects serum neutralization capability in
FIV-infected cats and that poor neutralizing antibody responses are generated in
either natural or experimental infection (Baldinotti et al., 1994). On the other
hand, broadly neutralizing antibodies were identified in some patients who had
been infected with HIV-1 for more than 9 years (Parren et al., 1998).
The role that maternal neutralizing antibodies may play in preventing HIV
transmission to infants is unresolved. While maternal autologous neutralizing
antibodies can be highly effective in preventing MTCT, variants that escape
these maternal antibodies can infect the fetus (Bal et al., 1996; Dickover et al.,
2006). Others also report that high titers of neutralizing antibodies did not
prevent fetal infection (Bal et al., 1996), and low maternal neutralizing antibody
did not increase the risk of transmission in women matched for CD4+T cell
percentage (Husson et al., 1995). Typically, the fetus is infected with a
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genetically homogeneous, non-syncytium-inducing, macrophage-tropic strain
selected from the maternal quasispecies (Reinhardt et al., 1994).
It has been speculated that serum factors other than antibodies may be
responsible for virus neutralization (Lunardi-Iskandar et al., 1998). Bradley et. al
(1982) found that depletion of IgG from amniotic fluids eliminated virus
neutralization capability of the AF, concluding that IgG antibodies were the sole
source of virus neutralization. We speculated that a possible blood component
that could contribute to reduced viral infectivity is complement. Virus-antibody
interactions could activate complement activity within the AF. However, we
eliminated potential antiviral action of complement by heat inactivating AF
samples prior to use in syncytium reduction assays.
In summary, the FIV load was either negligible or below the level of
detection in all AF collected at early or late gestation, and thus, direct infection of
the fetus by exposure to contaminated AF seems unlikely. FIV-specific antibody
was commonly present in AF samples, although AF from different fetuses had
different amounts of antibody, or none at all. Virus-neutralizing antibodies were
detected in the three early-gestation AF tested from the FIV-infected group, while
virus neutralization did not reach the level of significance among the late-term AF
samples. The presence of VN antibodies in AF did not correlate with fetal
infection. Despite the presence of VN antibodies in AF, the corresponding earlyterm fetuses were infected with FIV. Collectively, these data suggest that the
amniotic fluid does not play a significant role in in utero FIV infection.

56

Acknowledgements
We thank Dr. Edward A. Hoover, Colorado State University, for providing
the infectious plasma pool containing FIV-B-2542. We are grateful to the
veterinary staff at the College of Veterinary Medicine, Mississippi State
University, for assistance with animal care and surgery. We thank Life Science
and Biotechnology Institute at Mississippi State University for the use of the
facilities and equipment. This project was supported by the National Institute of
Health, project # 2R15AI048410-02A.

57

References
Bal, A. K., Miller, G., Viscarello, R. & Andiman, W. A. (1996). Syncytiuminhibiting and neutralizing activity in maternal sera fail to prevent vertical
transmission of human immunodeficiency virus type 1. Pediatr Infect Dis J
15, 315-320.
Baldinotti, F., Matteucci, D., Mazzetti, P., Giannelli, C., Bandecchi, P.,
Tozzini, F. & Bendinelli, M. (1994). Serum neutralization of feline
immunodeficiency virus is markedly dependent on passage history of the
virus and host system. J Virol 68, 4572-4579.
Barin, F., Jourdain, G., Brunet, S., Ngo-Giang-Huong, N., Weerawatgoompa,
S., Karnchanamayul, W., Ariyadej, S., Hansudewechakul, R.,
Achalapong, J., Yuthavisuthi, P., Ngampiyaskul, C., Bhakeecheep, S.,
Hemwutthiphan, C. & Lallemant, M. (2006). Revisiting the role of
neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect
Dis 193, 1504-1511.
Bendinelli, M., Pistello, M., Lombardi, S., Poli, A., Garzelli, C., Matteucci, D.,
Ceccherini-Nelli, L., Malvaldi, G. & Tozzini, F. (1995). Feline
immunodeficiency virus: an interesting model for AIDS studies and an
important cat pathogen. Clin Microbiol Rev 8, 87-112.
Boudreaux, C. E., Lockett, N. N., Chemerys, D. N., Clay, B. T., Scott, V. L.,
Willeford, B., Brown, T. & Coats, K. S. (2009). Maternal hematological
and virological characteristics during early feline immunodeficiency virus
(FIV) infection of cats as predictors of fetal infection and reproductive
outcome at early gestation. Vet Immunol Immunopathol 131, 290-297.
Bradley, J. S., Yeager, A. S., Dyson, D. C., Hensleigh, P. A. & Medearis, A. L.
(1982). Neutralization of herpes simplex virus by antibody in amniotic fluid.
Obstet Gynecol 60, 318-321.
Burkhard, M. J. & Hoover, E. A. (2005). IgG from acutely infected cats blocks
mucosal feline immunodeficiency virus infection. Vet Immunol
Immunopathol 106, 87-95.
Burns, D. P. & Desrosiers, R. C. (1994). Envelope sequence variation,
neutralizing antibodies, and primate lentivirus persistence. Curr Top
Microbiol Immunol 188, 185-219.
CDC (March 2007). When Pregnant Patients are Unsure About HIV Screening.
58

Dabis, F., Msellati, P., Dunn, D., Lepage, P., Newell, M. L., Peckham, C. &
Van de Perre, P. (1993). Estimating the rate of mother-to-child
transmission of HIV. Report of a workshop on methodological issues
Ghent (Belgium), 17-20 February 1992. The Working Group on Mother-toChild Transmission of HIV. Aids 7, 1139-1148.
Dickover, R., Garratty, E., Yusim, K., Miller, C., Korber, B. & Bryson, Y.
(2006). Role of maternal autologous neutralizing antibody in selective
perinatal transmission of human immunodeficiency virus type 1 escape
variants. J Virol 80, 6525-6533.
Hussain, K. A., Issel, C. J., Schnorr, K. L., Rwambo, P. M. & Montelaro, R. C.
(1987). Antigenic analysis of equine infectious anemia virus (EIAV)
variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of
EIAV stimulate neutralizing antibodies. J Virol 61, 2956-2961.
Husson, R. N., Lan, Y., Kojima, E., Venzon, D., Mitsuya, H. & McIntosh, K.
(1995). Vertical transmission of human immunodeficiency virus type 1:
autologous neutralizing antibody, virus load, and virus phenotype. J
Pediatr 126, 865-871.
Jaspan, H. B., Robinson, J. E., Amedee, A. M., Van Dyke, R. B. & Garry, R.
F. (2004). Amniotic fluid has higher relative levels of lentivirus-specific
antibodies than plasma and can contain neutralizing antibodies. J Clin
Virol 31, 190-197.
John, G. C. & Kreiss, J. (1996). Mother-to-child transmission of human
immunodeficiency virus type 1. Epidemiol Rev 18, 149-157.
Kamara, P., Melendez-Guerrero, L., Arroyo, M., Weiss, H. & Jolly, P. (2005).
Maternal plasma viral load and neutralizing/enhancing antibodies in
vertical transmission of HIV: a non-randomized prospective study. Virol J
2, 15.

Kind, C., Rudin, C., Siegrist, C. A., Wyler, C. A., Biedermann, K., Lauper, U.,
Irion, O., Schupbach, J. & Nadal, D. (1998). Prevention of vertical HIV
transmission: additive protective effect of elective Cesarean section and
zidovudine prophylaxis. Swiss Neonatal HIV Study Group. Aids 12, 205210.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of
the head of bacteriophage T4. Nature 227, 680-685.

59

Lunardi-Iskandar Y., Bryant, J.L., Blattner, W.A., Hung, C.L., Flammand, L.,
Gill, P. (1998). Effects of a urinary factor from women in early pregnancy
on HIV-1, SIV and associated disease. Nat Med 4, 428-434
Mandelbrot, L., Burgard, M., Teglas, J. P., Benifla, J. L., Khan, C., Blot, P.,
Vilmer, E., Matheron, S., Firtion, G., Blanche, S., Mayaux, M. J. &
Rouzioux, C. (1999). Frequent detection of HIV-1 in the gastric aspirates
of neonates born to HIV-infected mothers. AIDS 13, 2143-2149.
Mohlala, B. K., Tucker, T. J., Besser, M. J., Williamson, C., Yeats, J., Smit,
L., Anthony, J. & Puren, A. (2005). Investigation of HIV in amniotic fluid
from HIV-infected pregnant women at full term. J Infect Dis 192, 488-491.
Mundy, D. C., Schinazi, R. F., Gerber, A. R., Nahmias, A. J. & Randall, H. W.,
Jr. (1987). Human immunodeficiency virus isolated from amniotic fluid.
Lancet 2, 459-460.
Parren, P. W., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., ChengMayer, C., Moore, J. P. & Burton, D. R. (2001). Antibody protects
macaques against vaginal challenge with a pathogenic R5 simian/human
immunodeficiency virus at serum levels giving complete neutralization in
vitro. J Virol 75, 8340-8347.
Parren, P. W., Wang, M., Trkola, A., Binley, J. M., Purtscher, M., Katinger, H.,
Moore, J. P. & Burton, D. R. (1998). Antibody neutralization-resistant
primary isolates of human immunodeficiency virus type 1. J Virol 72,
10270-10274.
Reinhardt, B., Torbett, B. E., Gulizia, R. J., Reinhardt, P. P., Spector, S. A. &
Mosier, D. E. (1994). Human immunodeficiency virus type 1 infection of
neonatal severe combined immunodeficient mice xenografted with human
cord blood cells. AIDS Res Hum Retroviruses 10, 131-141.
Rogers, A. B. & Hoover, E. A. (2002). Fetal feline immunodeficiency virus is
prevalent and occult. J Infect Dis 186, 895-904.
Scarlatti, G., Albert, J., Rossi, P., Hodara, V., Biraghi, P., Muggiasca, L. &
Fenyo, E. M. (1993). Mother-to-child transmission of human
immunodeficiency virus type 1: correlation with neutralizing antibodies
against primary isolates. J Infect Dis 168, 207-210.
Sprecher S, S. G., Puissant F, Degueldre M (1986). Vertical transmission of
HIV in 15-week fetus. Lancet 2, 288-289.

60

Tozzini, F., Matteucci, D., Bandecchi, P., Baldinotti, F., Siebelink, K.,
Osterhaus, A. & Bendinelli, M. (1993). Neutralizing antibodies in cats
infected with feline immunodeficiency virus. J Clin Microbiol 31, 16261629.
UNAIDS/WHO (2000). AIDS epidemic update: December 2000. Geneva: Joint
United Nations Programme on HIV/AIDS, World Health Organization.
Weaver, C. C., Burgess, S. C., Nelson, P. D., Wilkinson, M., Ryan, P. L., Nail,
C. A., Kelly-Quagliana, K. A., May, M. L., Reeves, R. K., Boyle, C. R. &
Coats, K. S. (2005). Placental immunopathology and pregnancy failure in
the FIV-infected cat. Placenta 26, 138-147.
Zheng, Y. H., Sentsui, H., Nakaya, T., Kono, Y. & Ikuta, K. (1997). In vivo
dynamics of equine infectious anemia viruses emerging during febrile
episodes: insertions/duplications at the principal neutralizing domain. J
Virol 71, 5031-5039.

61

CHAPTER III
SUMMARY

In the U.S., 99% of HIV-infected children were infected due to MTCT
(CDC, 2007b). In the absence of administration of anti-retroviral therapy to HIVinfected, pregnant women, the rate of MTCT is 15-40% (Brocklehurst & Volmink,
2002; Burns & Mofenson, 1999; Connor et al., 1994; Jaspan & Garry, 2003;
Newell, 1998; Simpson et al., 2000). However, between 1994 and 2007,
aggressive anti-retroviral therapy and cesarean delivery resulted in an estimated
96% decrease in perinatal transmission (CDC, 2007a). Maternal virological and
serological factors such as viral load, virus strain, and CD4+ T cell counts, are
predictors of MTCT (Deeks et al., 2004; McCune, 2001; Yates et al., 2007). HIVand SIV-contaminated amniotic fluids were detected, and virus neutralizing
antibodies were found in AF of both humans and macaques. Virus neutralizing
antibody concentrations were significantly higher in the AF than plasma of HIVinfected humans or SIV-infected macaques (Jaspan et al., 2004). Yet, a direct
relationship between the presence or absence of HIV or virus neutralizing
antibodies in AF has not been resolved. HIV-1-infected gastric aspirates were
reported in neonates (Mandelbrot et al., 1999). Thus, a role for AF in promoting
or limiting perinatal transmission remains controversial.
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Using the FIV-infected cat to model lentiviral MTCT, we reported very high
fetal infection rates in both early and late, cesarean section-delivered fetuses
(Boudreaux et al., 2009; Weaver et al., 2005). The apparent frequency of vertical
transfer in experimentally-infected cats and the fact that cats produce multiple
offspring in a single litter (limiting the confounding variables innate to individual
queens) makes this animal model useful for evaluating the role of AF in MTCT.
We suspected that contaminated AF may provide a source of fetal infection, but
also predicted that virus neutralizing antibodies, potentially present in AF, could
limit this means of vertical transmission. Our goals were to determine whether
FIV antigen is present in AF, to analyze AF and corresponding sera for FIV p24specific antibodies, and to determine whether AF and sera had virus neutralizing
activity.
We used both real time RT-PCR to detect viral RNA and an FIV p24capture ELISA to look for the presence of FIV in the amniotic fluid associated
with early- and late-term fetuses. We were unable to detect the virus by either
assay method, indicating the virus was either completely absent or at a level
beneath the limit of detection. We also evaluated the AF for FIV p24-specific
antibody using two different ELISA techniques. We detected anti-FIV p24
antibody in most early- and late-term AF (63% and 61%, respectively).
Corresponding early- and late- term serum samples were also positive for the
FIV-specific antibody by Western blot and SNAP ELISA. However, the 96 well
PetChek FIV Antibody Test kit, used to test the early sera only, was less
sensitive (33% positive).
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After determining that FIV-specific antibody was present in AF, we
evaluated the virus neutralization capability of randomly- selected AF samples
and corresponding serum from early pregnancies by conducting in vitro
syncytium-reduction assays. These assays involved incubating triplicate cultures
of FIV- infected CrFK cells with AF or serum diluted in a 4-fold series or medium
lacking either fluid. Following incubation of the cultures for 1 week, all wells were
stained and observed microscopically for the development of syncytia. All
syncytia within the triplicate cultures were counted, averaged, and analyzed
statistically. Virus neutralization by the fluids was evident by a reduction in the
number of syncytia. All early-term AF had virus neutralizing activity. One serum
sample neutralized the virus. None of the AF samples collected from lategestation fetal membranes reduced syncytia to a level that reached significance.
It is possible that long-term storage diminished the antibody quality in late-term
samples as they were preserved at -20°C for more than 5 years. Virus
neutralization assays for corresponding late-term sera were not done.
In summary, we failed to detect FIV in AF, suggesting that virus was not
present in these fluids. We detected FIV-p24 specific antibody in the majority of
AF from both early and late pregnancy. We observed virus neutralizing activity in
three of three early-term AF and one corresponding serum, but not late-term AF.
We observed a very high rate of fetal infection at both stages of pregnancy.
Thus, it appears that amniotic fluids play no appreciable role in promoting or
limiting vertical transfer of FIV.
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